RASAD 2012 Presentations


[table]

Cognition Session, Tuesday 27 March

08.45 – 09.15, John Morris – Diagnostic Criteria and Biomarkers

09.15 – 09.45, Ron Petersen – Challenges of Longitudinal Data Sets

09.45 – 10.15, Greg Savage – Being too smart for your own good: issues in the cognitive assessment of high functioning individuals

10.15 – 10.30, Leon Flicker – Cochrane Group: Reviews of standards for the reporting of diagnostic accuracy studies

11.50 – 12.00, Maria Carrillo and Art Toga – Global Alzheimer’s Association Interactive Network (GAAIN)

Imaging Session, Tuesday 27 March

13.05 – 13.40, Reisa Sperling – The role of neuroimaging in AD and why we need standardization

13.40 –14.10, Cliff Jack – Translating 20 years of research with volumetric MRI into multicentre trials and routine clinical practice. Has ADNI solved all the problems?

14.10 – 14.30, Charles DeCarli – Visual vs volumetric MRI in the clinic and for research

14.30 – 14.50, Giovanni Frisconi – The European perspective on Standardization of Neuroimaging including commentary on EMA statements on vMRI

15.10 – 15.50, Cliff Jack – Automated MRI analysis: the academic and commercial options

15.50 – 16.20, Bill Jagust – Multicenter standardization of PET data processing

16.40 – 16.50, Christopher Rowe – Amyloid PET in clinical practice: is a binary yes or no report enough? Should the patients’ age influence the interpretation? Can the different tracers be compared?

17.20 – 17.50, Mark Schmidt – Amyloid PET in therapeutic trials – what has been learnt so far?

Biomarker Session, Wednesday 28 March

08.30 – 09.00, Jerome Barakos and John Seibyl – Current Industry Neuroimaging Experience in Clinical Trials

10.35 – 11.05, Kaj Blennow – CSF diagnostics: Overview and use in monitoring therapeutic interventions

11.05 – 11.30, Takeshi Iwatsubo – Japanese perspective on CSF diagnostics

11.30 – 11.55, Bill Potter – Perspective from Industry

11.55 – 12.20, Henrik Zetterberg – Quality controls and validation of CSF tests

12.20 – 12.30, Steve Collins – Lessons from running CSF diagnostics for CJD: National and International perspectives

13.55 – 14.20, Les Shaw – Validation studies arising from ADNI experience

14.20 – 14.50, Simon Lovestone – Candidate gene/protein vs proteomic approaches

14.50 – 15.20, an-Jiang Wang – Epidemiology Clinical Management and Research Standardisation of Alzheimer’s Disease in China

15.20 – 15.45, Sid O’Bryant – Proteomic approaches

15.45 – 16.10, Ralph Martins – Perth AIBL approach. Lipidomic approaches and ApoE

Lifestyle Session, Thursday 29 March

08.40 – 08.50, Ralph Martins – Lifestyle Factors in Alzheimer’s Disease

08.50– 09.35, Nick Scarmeas – What is the current level of evidence for dietary intervention to delay the onset of Alzheimer’s disease? How can we improve our measures?

09.35 – 09.55, Nicola Lautenschlager – Could physical activity delay cognitive decline in older adults with vascualr risk factors?

[/table]

 

© Copyright AIBL - Theme by Pexeto